These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 29364894)

  • 1. Serum calcification propensity is independently associated with disease activity in systemic lupus erythematosus.
    Dahdal S; Devetzis V; Chalikias G; Tziakas D; Chizzolini C; Ribi C; Trendelenburg M; Eisenberger U; Hauser T; Pasch A; Huynh-Do U; Arampatzis S;
    PLoS One; 2018; 13(1):e0188695. PubMed ID: 29364894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ITGAM rs1143679 Variant in Systemic Lupus Erythematosus Is Associated with Increased Serum Calcification Propensity.
    Halfon M; Zhang L; Ehirchiou D; Pandian VD; Dahdal S; Huynh-Do U; Pasch A; Ribi C; Busso N
    Genes (Basel); 2023 May; 14(5):. PubMed ID: 37239465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations of the Levels of C4d-bearing Reticulocytes and High-avidity Anti-dsDNA Antibodies with Disease Activity in Systemic Lupus Erythematosus.
    Mora C; Medina-Rosas J; Santos AM; Jaimes DA; Arbeláez AM; Romero C; Cortes A; Londono J
    J Rheumatol; 2016 Sep; 43(9):1657-64. PubMed ID: 27134246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Swiss Systemic lupus erythematosus Cohort Study (SSCS) - cross-sectional analysis of clinical characteristics and treatments across different medical disciplines in Switzerland.
    Ribi C; Trendelenburg M; Gayet-Ageron A; Cohen C; Dayer E; Eisenberger U; Hauser T; Hunziker T; Leimgruber A; Lindner G; Koenig K; Otto P; Spertini F; Stoll T; Von Kempis J; Chizzolini C;
    Swiss Med Wkly; 2014; 144():w13990. PubMed ID: 25115978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.
    Petri M; Stohl W; Chatham W; McCune WJ; Chevrier M; Ryel J; Recta V; Zhong J; Freimuth W
    Arthritis Rheum; 2008 Aug; 58(8):2453-9. PubMed ID: 18668552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of disease activity on health-related quality of life in systemic lupus erythematosus - a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS).
    Chaigne B; Chizzolini C; Perneger T; Trendelenburg M; Huynh-Do U; Dayer E; Stoll T; von Kempis J; Ribi C;
    BMC Immunol; 2017 Mar; 18(1):17. PubMed ID: 28351341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urine β2-microglobulin is associated with clinical disease activity and renal involvement in female patients with systemic lupus erythematosus.
    Choe JY; Park SH; Kim SK
    Lupus; 2014 Dec; 23(14):1486-93. PubMed ID: 25124677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcification Propensity and Survival among Renal Transplant Recipients.
    Keyzer CA; de Borst MH; van den Berg E; Jahnen-Dechent W; Arampatzis S; Farese S; Bergmann IP; Floege J; Navis G; Bakker SJ; van Goor H; Eisenberger U; Pasch A
    J Am Soc Nephrol; 2016 Jan; 27(1):239-48. PubMed ID: 25925688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validity and reliability of retrospective assessment of disease activity and flare in observational cohorts of lupus patients.
    FitzGerald JD; Grossman JM
    Lupus; 1999; 8(8):638-44. PubMed ID: 10568901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral Sodium Bicarbonate Supplementation Does Not Affect Serum Calcification Propensity in Patients with Chronic Kidney Disease and Chronic Metabolic Acidosis.
    Aigner C; Cejka D; Sliber C; Fraunschiel M; Sunder-Plassmann G; Gaggl M
    Kidney Blood Press Res; 2019; 44(2):188-199. PubMed ID: 31067546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
    Enocsson H; Wetterö J; Skogh T; Sjöwall C
    Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum calcification propensity predicts all-cause mortality in predialysis CKD.
    Smith ER; Ford ML; Tomlinson LA; Bodenham E; McMahon LP; Farese S; Rajkumar C; Holt SG; Pasch A
    J Am Soc Nephrol; 2014 Feb; 25(2):339-48. PubMed ID: 24179171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum free light chains as biomarkers for systemic lupus erythematosus disease activity.
    Aggarwal R; Sequeira W; Kokebie R; Mikolaitis RA; Fogg L; Finnegan A; Plaas A; Block JA; Jolly M
    Arthritis Care Res (Hoboken); 2011 Jun; 63(6):891-8. PubMed ID: 21312346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus.
    Von Feldt JM; Scalzi LV; Cucchiara AJ; Morthala S; Kealey C; Flagg SD; Genin A; Van Dyke AL; Nackos E; Chander A; Gehrie E; Cron RQ; Whitehead AS
    Arthritis Rheum; 2006 Jul; 54(7):2220-7. PubMed ID: 16802358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Negative correlation between fetuin-A and indices of vascular disease in systemic lupus erythematosus patients with and without lupus nephritis.
    Abdel-Wahab AF; Fathy O; Al-Harizy R
    Arab J Nephrol Transplant; 2013 Jan; 6(1):11-20. PubMed ID: 23282228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Worsening calcification propensity precedes all-cause and cardiovascular mortality in haemodialyzed patients.
    Lorenz G; Steubl D; Kemmner S; Pasch A; Koch-Sembdner W; Pham D; Haller B; Bachmann Q; Mayer CC; Wassertheurer S; Angermann S; Lech M; Moog P; Bauer A; Heemann U; Schmaderer C
    Sci Rep; 2017 Oct; 7(1):13368. PubMed ID: 29042624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Classification of Systemic Lupus Erythematosus: Systemic Lupus International Collaborating Clinics Versus American College of Rheumatology Criteria. A Comparative Study of 2,055 Patients From a Real-Life, International Systemic Lupus Erythematosus Cohort.
    Inês L; Silva C; Galindo M; López-Longo FJ; Terroso G; Romão VC; Rúa-Figueroa I; Santos MJ; Pego-Reigosa JM; Nero P; Cerqueira M; Duarte C; Miranda LC; Bernardes M; Gonçalves MJ; Mouriño-Rodriguez C; Araújo F; Raposo A; Barcelos A; Couto M; Abreu P; Otón-Sanchez T; Macieira C; Ramos F; Branco JC; Silva JA; Canhão H; Calvo-Alén J; ;
    Arthritis Care Res (Hoboken); 2015 Aug; 67(8):1180-5. PubMed ID: 25581417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lupus Impact Tracker is responsive to physician and patient assessed changes in systemic lupus erythematosus.
    Giangreco D; Devilliers H; Annapureddy N; Block JA; Jolly M
    Lupus; 2015 Dec; 24(14):1486-91. PubMed ID: 26162686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
    Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort study.
    Závada J; Uher M; Svobodová R; Olejárová M; Hušáková M; Ciferská H; Hulejová H; Tomčík M; Šenolt L; Vencovský J
    Arthritis Res Ther; 2015 Nov; 17():341. PubMed ID: 26608564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.